Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Raw Materials (2012 - 2015)

Updated

Grace Therapeutics (GRCE) reported Raw Materials of $31,348 for fiscal Q4 2015 (quarter ended Feb 28, 2015), down 12.3% from $35,739 a year earlier.

Analysis

Grace Therapeutics (GRCE) Raw Materials (2012 - 2015) Analysis & Trends

Dating back to fiscal Q4 2012, Grace Therapeutics' Raw Materials record includes 4 quarters.

  • Raw Materials has declined for three consecutive fiscal years, with a three-year compound annual growth rate of -18.5% (FY2012 to FY2015).
  • By fiscal year, Raw Materials came in at $39,753 in FY2014 (-11.2%), $44,772 in FY2013 (-22.7%) and $57,950 in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Feb 28, 2015 31,348.48
Feb 28, 2014 35,739.46
Feb 28, 2013 43,746.15
Feb 29, 2012 57,950.00
API Access

Grace Therapeutics Raw Materials API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=raw-materials&ticker=GRCE&period=max&api_key=YOUR_API_KEY